Infusional FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizumab and Apatinib for Advanced HCC
This is a multi-center randomized phase III clinical study of first-line intravenous FOLFOX plus Camrelizumab and apatinib versus HAIC-FOLFOX plus Camrelizumab and apatinib for BCLC C stage hepatocellular carcinoma.
BCLC Stage C Hepatocellular Carcinoma|Chemotherapy Effect
DRUG: intravenous FOLFOX7 plus Camrelizumab and apatinib|DRUG: HAIC-FOLFOX plus Camrelizumab and apatinib
ORR, objective response rate based on RECISTv1.1, up to approximately 3 years
mORR, objective response rate based on mRECIST, up to approximately 3 years|DOR, Proportion of patients who achieved complete response (CR) or partial response (PR) at the end of treatment, based on mRECIST criteria. Patients were evaluated once every 3 cycles during the 1st to 6th treatment cycle and once every 3 months during the sequential treatment phase., up to approximately 3 years|DCR, The percentage of patients whose tumors shrink or stabilize for a certain period of time, including complete response (CR), partial response (PR), and stable (SD) cases. Patients were evaluated once every 3 cycles during the 1st to 6th treatment cycle and once every 3 months during the sequential treatment phase., up to approximately 3 years|1y-PFSR, The proportion of patients who did not develop tumor progression from enrollment to 1 year of follow-up., 1 year|2y-OSR, Proportion of patients surviving from the start of enrollment to the full 2 years of follow-up., 2 year|OS, The time between the start of treatment and the patient's death, up to approximately 5 years|PFS, The time from the start of treatment to the first progression of the patient's disease, up to approximately 3 years|TRAE, The classification of adverse events during treatment was based on NCI-CTCAE v5.0 criteria., up to approximately 3 years|conversion rate, rate of unresectable converted into resectable, up to approximately 3 years
This is a multi-center randomized phase III clinical study of first-line intravenous FOLFOX plus Camrelizumab and apatinib versus HAIC-FOLFOX plus Camrelizumab and apatinib for BCLC C stage hepatocellular carcinoma.